Murine pancreatic cancer cells from two genetically engineered mouse models, representing common PDAC mutations, were utilized—one with KRAS and TP53 mutations and the other with KRAS and CDKN2A mutations, displaying distinct mesenchymal and epithelial phenotypes. This evidence concerns the gene KRAS and pancreatic neoplasm.